1 / 18

Dermatomyositis

Dermatomyositis. Emily O. Jenkins MD AM Report 9.2.09. Dermatomyositis. Hematoxylin and eosin stain (20x) of a muscle biopsy from a patient with dermatomyositis showing perivascular and perimysial inflammation, as well as perifascicular necrosis. Inflammatory myopathy

juliet
Download Presentation

Dermatomyositis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Dermatomyositis Emily O. Jenkins MD AM Report 9.2.09

  2. Dermatomyositis Hematoxylin and eosin stain (20x) of a muscle biopsy from a patient with dermatomyositis showing perivascular and perimysial inflammation, as well as perifascicular necrosis. • Inflammatory myopathy • Prevalence: 1:100,000 in general population • Female to male prevalence of 2:1 • peak incidence ages 40-50 • Immune complex deposition in the vessels considered to be part of a complement-mediated vasculopathy

  3. Diagnostic Criteria • Bohan and Peter Criteria: • Symmetric proximal muscle weakness • most common symptom • typical rash • elevated serum muscle enzymes • myopathic changes on EMG • characteristic muscle biopsy abnormalities and absence of histopathologic signs of other myopathies

  4. Signs and Symptoms • Grotton’s Sign: • An erythematous, scaly eruption over the extensor surfaces of the metacarpophalangeal joints and digits • can mimic psoriasis

  5. Signs and Symptoms • Heliotrope rash: • A reddish-purple eruption on the upper eyelid • accompanied by swelling of the eyelid • Most specific rash in DM • Only present in a minority of patients.

  6. Generalized Erythroderma • Facial erythema

  7. Shawl Sign

  8. Flagellate Erythema • Erythematous linear streaks on the trunk • probably induced by scratching pruritic skin • Skin biopsy usually demonstrates an interface dermatitis, typical of other skin lesions in dermatomyositis

  9. “Mechanic’s Hands” • roughened, cracked skin at tips and lateral aspects of the fingers resulting in irregular, dirty-appearing lines

  10. Nail Changes Capillary Loop Dilatation

  11. Nail Changes Periungual Erythema

  12. Immunopathogenesis • Humorally-mediated disorder with cellular infiltrate focused around blood vessels • Proinflammatory cytokines contribute to muscle weakness • IL-1 and TNF-alpha are increased in muscle tissue • Upregulation of MHC class I molecules on myocytes lead to disturbed muscle function

  13. Complications • Interstitial lung disease • 10% of cases • respiratory failure may result from diaphragmatic and chest muscle weakness • can result in rapid respiratory failure and death • Esophageal disease • weakness of the striated muscle of the upper 1/3 of the esophagus and/or oropharyngeal muscles • can lead to nasal regurgitation, dysphagia, aspiration •  More common in elderly patients • leads to increased incidence of bacterial pneumonia • Myocarditis • Malignancy

  14. Outcome Predictors • Worse outcomes if: • delay in initial treatment of >6 months after symptom onset • greater weakness at presentation • presence of dysphagia • respiratory muscle weakness • interstitial lung disease • associated malignancy • cardiac involvement • advanced age

  15. Malignancy in DM Patients • Incidence: of patients with DM, 48%  over age 65 v. 9% under age 65 were found to have a malignancy • Risk factors: • Evidence of capillary damage on muscle biopsy • DM complicated by cutaneous necrosis on the trunk • Cutaneousleukocytoclasticvasculitis • Older age at diagnosis • Pathophysiology: paraneoplastic process • Regenerating cells in myositis muscle, but not in normal muscle, express high levels of myositis-specific autoantigens. Same antigens are expressed at high levels in several cancers • Types of cancer: adenocarcinoma of the cervix, lung, ovaries, pancreas, bladder and stomach make up about 70% of associated cancers

  16. Cancer Screening in DM Patients • Thorough medical history and physical exam • Age appropriate cancer screening (mammogram and colonoscopy) • CT of chest, abdomen and pelvis recommended only if significantly increased risk • Pelvic US and transvaginal US for women • Serum CA 125 and CA 19-9 • PSA • UA for blood

  17. Treatment • Improve muscle strength and avoid development of extramuscular complications • Glucocorticoids are the cornerstone of initial therapy • Typically initiate prednisone at 1 mg/kg to a maximum dose of 80 mg • Initial treatment with high doses for the first several months to establish disease control • Slow taper to the lowest effective dose for total duration of 9-12 months • Assessing treatment response: muscle strength generally a better predictor than serum muscle enzyme concentrations • More than 80% of patients will improve with glucocorticoids alone • Among those who do respond, the majority do not return to normal strength

  18. Glucocorticoid Sparing Agents • Starting a sparing agent at the time prednisone is initiated is recommended • First line agents include azothioprine or methotrexate • Azothioprine is preferred if patients have ILD, underlying liver disease, or are unwilling to abstain from alcohol • A randomized trial compared prednisone + azothioprine to pred alone; no difference in clinical outcomes at 3 months, but at 3 years combination group required less maintenance prednisone • Response to azothioprine may take as long as 4-6 months • Before beginning azothoprine, patients should be screened for thiopurinemethytransferase deficiency (TPMT); if heterogeneous for this allele, pts can tolerate azothioprine but require lower daily doses • Homozygous negative pts, occuring in 1:300 people, cannot metabolize the drug and should not receive under any circumstances  can lead to disasterous BM toxicity • Initial dose of azothioprine is 50 mg/day

More Related